Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE

BACKGROUND: In the IMAGE study, rituximab plus methotrexate (MTX) inhibited joint damage and improved clinical outcomes at 1 year in MTX-naïve patients with early active rheumatoid arthritis. OBJECTIVE: The aim of this study was to assess joint damage progression and clinical outcomes over 2 years....

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Tak, Paul P, Rigby, William, Rubbert-Roth, Andrea, Peterfy, Charles, van Vollenhoven, Ronald F, Stohl, William, Healy, Emma, Hessey, Eva, Reynard, Mark, Shaw, Tim
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Group 2011
Konular:
Clinical and Epidemiological Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3277723/
https://ncbi.nlm.nih.gov/pubmed/22012969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2011-200170
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller